在非小细胞肺癌中,EGFR寡合化的固体干扰克服了治疗阻力
Daesun Song1,2, Jaebong Jang3, Michael Z Lin1,2,4
1Department of Neurobiology, Stanford University, Stanford, CA 94305, USA.
Science advances
|December 5, 2025
概括
肺癌中的EGFR耐药性突变显示出增加的寡合化. 用重的结合剂破坏这种EGFR寡合,可以克服耐药性,提供一种新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药物发现 药物发现
背景情况:
- 在表皮生长因子受体 (EGFR) 中获得的耐药性突变是非小细胞肺癌 (NSCLC) 治疗的一个主要挑战.
- 已知EGFR寡合化调节受体信号传递,但其在抗性突变中的作用尚不清楚.
研究的目的:
- 研究致癌和耐药EGFR突变体的寡合化及其下游信号之间的实时关系.
- 探索克服EGFR介导NSCLC中药物耐药性的策略.
主要方法:
- 利用基于光蛋白的近距离探测器和信号记者在活细胞中实时监测EGFR寡合化和信号.
- 评估了EGFR寡合化水平与氨酸激酶抑制剂 (TKI) 和全药物的疗效之间的相关性.
- 研究了使用庞大的蛋白质和细胞外EGFR结合剂的基因融合对干扰EGFR寡合化的效果.
主要成果:
- 与野生型EGFR相比,对TKI耐药的EGFR突变体表现出较高的寡合化水平.
- 试验基因抑制剂和全性药物的疗效与EGFR受体寡合化的程度相反.
- 通过基因融合或细胞外结合剂,对EGFR寡合化的固体干扰有效地克服了耐药性并抑制了癌细胞的增殖.
结论:
- 干扰EGFR寡聚化是一种有前途的治疗策略,可以克服NSCLC的耐药性.
- 该研究引入了一种新的查平台,用于开发针对EGFR的竞争性和全抑制剂.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.5K
相关概念视频
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
